FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2560319905> ?p ?o ?g. }

• W2560319905 abstract "Pacritinib (SB1518) is a highly selective kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CFS1R. This multicenter phase 1/2 study evaluated the maximum tolerated dose (MTD), safety, and clinical activity of pacritinib in patients with myelofibrosis (MF) and other advanced myeloid malignancies. In the phase 1 dose-escalation part of the study, 43 adults with advanced myeloid malignancies received pacritinib 100 to 600 mg once daily (QD). In the phase 2 part of the study, 31 adults with refractory or intermediate- or high-risk newly diagnosed MF and any degree of cytopenia received pacritinib 400 mg QD. The primary endpoint is a ≥35% reduction in spleen volume at week 24 as determined by magnetic resonance imaging. Five patients (11.6%) experienced a dose-limiting toxicity during cycle 1 of phase 1. The clinical benefit rate was 86.0% (13 patients achieving clinical improvement and 24 patients having stable disease). The MTD was established at 500 mg QD, and the recommended phase 2 dose was 400 mg QD. In phase 2, the primary endpoint was achieved by 23.5% of evaluable patients (4/17), with 47.4% (9/19) achieving a ≥50% spleen length reduction at week 24 as measured by physical examination. At week 24, 38.9% of evaluable patients (7/18) achieved a ≥50% decrease in MF Quality of Life and Symptom Assessment total score. Gastrointestinal toxicities were the most common adverse events and were predominantly grade 1/2 in severity. Grade 3/4 anemia was reported in 5/31 patients and grade 3/4 thrombocytopenia was reported in 3/31 patients. The most frequent AEs considered to be treatment related were diarrhea (28/31), nausea (15/31), vomiting (9/31), and fatigue (4/31). Grade 3 treatment-related AEs were reported in seven patients (22.6%), four of whom had diarrhea. No grade 4/5 treatment-related AEs were reported. No leukopenia, neutropenia, or lymphopenia were reported. Pacritinib was well tolerated and demonstrated clinical activity in MF. The study suggests that pacritinib has unique characteristics, namely a lack of substantial myelosuppression and manageable side effects, making it an attractive target for further evaluation in MF. Retrospectively registered at www.clinicaltrials.gov (# NCT00719836 ) on July 20, 2008." @default.
• W2560319905 created "2016-12-16" @default.
• W2560319905 creator A5005050727 @default.
• W2560319905 creator A5014292494 @default.
• W2560319905 creator A5045366442 @default.
• W2560319905 creator A5050374901 @default.
• W2560319905 creator A5060015628 @default.
• W2560319905 creator A5085521139 @default.
• W2560319905 date "2016-12-01" @default.
• W2560319905 modified "2023-10-11" @default.
• W2560319905 title "Phase 1/2 study of pacritinib, a next generation JAK2/FLT3 inhibitor, in myelofibrosis or other myeloid malignancies" @default.
• W2560319905 cites W1973160387 @default.
• W2560319905 cites W1980568348 @default.
• W2560319905 cites W1981229807 @default.
• W2560319905 cites W1996102187 @default.
• W2560319905 cites W2018254868 @default.
• W2560319905 cites W2029985592 @default.
• W2560319905 cites W2041027929 @default.
• W2560319905 cites W2045469701 @default.
• W2560319905 cites W2051743028 @default.
• W2560319905 cites W2057360098 @default.
• W2560319905 cites W2061554242 @default.
• W2560319905 cites W2076003438 @default.
• W2560319905 cites W2105414227 @default.
• W2560319905 cites W2105949419 @default.
• W2560319905 cites W2116043577 @default.
• W2560319905 cites W2116878961 @default.
• W2560319905 cites W2129510594 @default.
• W2560319905 cites W2132912591 @default.
• W2560319905 cites W2134540087 @default.
• W2560319905 cites W2138800281 @default.
• W2560319905 cites W2144664431 @default.
• W2560319905 cites W2157694607 @default.
• W2560319905 cites W2159507916 @default.
• W2560319905 cites W2159659449 @default.
• W2560319905 cites W2161021913 @default.
• W2560319905 cites W2566060809 @default.
• W2560319905 cites W2568518915 @default.
• W2560319905 cites W2889560895 @default.
• W2560319905 cites W2890676078 @default.
• W2560319905 cites W2979608637 @default.
• W2560319905 cites W3114368461 @default.
• W2560319905 cites W4237200993 @default.
• W2560319905 cites W4293541898 @default.
• W2560319905 cites W4376595466 @default.
• W2560319905 doi "https://doi.org/10.1186/s13045-016-0367-x" @default.
• W2560319905 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5146859" @default.
• W2560319905 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27931243" @default.
• W2560319905 hasPublicationYear "2016" @default.
• W2560319905 type Work @default.
• W2560319905 sameAs 2560319905 @default.
• W2560319905 citedByCount "57" @default.
• W2560319905 countsByYear W25603199052017 @default.
• W2560319905 countsByYear W25603199052018 @default.
• W2560319905 countsByYear W25603199052019 @default.
• W2560319905 countsByYear W25603199052020 @default.
• W2560319905 countsByYear W25603199052021 @default.
• W2560319905 countsByYear W25603199052022 @default.
• W2560319905 countsByYear W25603199052023 @default.
• W2560319905 crossrefType "journal-article" @default.
• W2560319905 hasAuthorship W2560319905A5005050727 @default.
• W2560319905 hasAuthorship W2560319905A5014292494 @default.
• W2560319905 hasAuthorship W2560319905A5045366442 @default.
• W2560319905 hasAuthorship W2560319905A5050374901 @default.
• W2560319905 hasAuthorship W2560319905A5060015628 @default.
• W2560319905 hasAuthorship W2560319905A5085521139 @default.
• W2560319905 hasBestOaLocation W25603199051 @default.
• W2560319905 hasConcept C126322002 @default.
• W2560319905 hasConcept C197934379 @default.
• W2560319905 hasConcept C203092338 @default.
• W2560319905 hasConcept C2776112149 @default.
• W2560319905 hasConcept C2778248108 @default.
• W2560319905 hasConcept C2779282312 @default.
• W2560319905 hasConcept C2780007613 @default.
• W2560319905 hasConcept C2780076729 @default.
• W2560319905 hasConcept C2780366003 @default.
• W2560319905 hasConcept C29730261 @default.
• W2560319905 hasConcept C31760486 @default.
• W2560319905 hasConcept C535046627 @default.
• W2560319905 hasConcept C71924100 @default.
• W2560319905 hasConcept C90924648 @default.
• W2560319905 hasConceptScore W2560319905C126322002 @default.
• W2560319905 hasConceptScore W2560319905C197934379 @default.
• W2560319905 hasConceptScore W2560319905C203092338 @default.
• W2560319905 hasConceptScore W2560319905C2776112149 @default.
• W2560319905 hasConceptScore W2560319905C2778248108 @default.
• W2560319905 hasConceptScore W2560319905C2779282312 @default.
• W2560319905 hasConceptScore W2560319905C2780007613 @default.
• W2560319905 hasConceptScore W2560319905C2780076729 @default.
• W2560319905 hasConceptScore W2560319905C2780366003 @default.
• W2560319905 hasConceptScore W2560319905C29730261 @default.
• W2560319905 hasConceptScore W2560319905C31760486 @default.
• W2560319905 hasConceptScore W2560319905C535046627 @default.
• W2560319905 hasConceptScore W2560319905C71924100 @default.
• W2560319905 hasConceptScore W2560319905C90924648 @default.
• W2560319905 hasIssue "1" @default.
• W2560319905 hasLocation W25603199051 @default.
• W2560319905 hasLocation W25603199052 @default.
• W2560319905 hasLocation W25603199053 @default.
• W2560319905 hasLocation W25603199054 @default.

• next